Skip to content

Different Reperfusion Timing and Ventricular Arrhythmias in STEMI Patients

Association of Reperfusion Timing With Short- and Medium-term Ventricular Arrhythmias in Patients With ST-segment Elevation Myocardial Infarction: A Prospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04660474
Enrollment
517
Registered
2020-12-09
Start date
2019-07-01
Completion date
2022-12-31
Last updated
2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmia Ventricular, ST Elevation Myocardial Infarction

Keywords

Symptom Onset-to-Reperfusion Timing (SO2RT), ST Elevation Myocardial Infarction, Arrhythmia Ventricular, Percutaneous Coronary Intervention, Early Reperfusion

Brief summary

The aim of this study was to investigate the association between different reperfusion timing and ventricular arrhythmias (VAs) to provide evidence for clinical decision-making for patients with ST-segment elevation myocardial infarction (STEMI). All the participants included in the study were diagnosed with STEMI according to the 4th universal definition of myocardial infarction, with a follow-up of 1, 6, 12 months, respectively. Symptom onset-to-reperfusion timing (SO2RT) and 24h-dynamic electrocardiogram parameters were recorded to compare different SO2RT and VAs during 3 follow-up visits.

Detailed description

It is Class I recommendation that STEMI require emergency revascularization with no delay. However, arrhythmias after acute myocardial infarction (AMI), particularly VAs, also occur in the early post-MI phase, leading to increased mortality. Previous studies have shown benefits of late reperfusion to electrical stability. The aim of this study was to investigate the association between different reperfusion timing and VAs to provide evidence for clinical decision-making for STEMI. In this multicenter, prospective, observational study, STEMI participants from July 2019 to December 2020 confirmed according to the 4th universal definition of myocardial infarction were enrolled, with a follow-up of 1, 6, 12 months, respectively. SO2RT was defined as the time interval between symptom onset and reperfusion timing which referred to the timing when coronary angiography showed Thrombolysis In Myocardial Infarction (TIMI) blood flow level 2\ 3 immediately after percutaneous coronary intervention (PCI). The primary end point was VAs on 24h-dynamic electrocardiogram. Secondary outcomes included a composite of death from coronary heart disease, fetal of non-fetal ischemic stroke, revascularization, or chest pain requiring readmission.

Interventions

None listed

Sponsors

The Affiliated Jiangning Hospital of Nanjing Medical University
CollaboratorOTHER
The Affiliated Hospital of Hangzhou Normal University
CollaboratorOTHER
Huai'an First People's Hospital
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* STEMI patients undergoing coronary angiography and PCI; * can complete 3 follow-up visits well.

Exclusion criteria

* without PCI; * undergoing thrombolytic therapy; * mental diseases; * renal failure; * stroke sequelae; * tumor and a history of revascularization.

Design outcomes

Primary

MeasureTime frameDescription
VAs12 monthsThe incidence of ventricular arrhythmias on 24h-dynamic electrocardiogram.

Secondary

MeasureTime frameDescription
Death from coronary heart disease12 monthsThe incidence of death from coronary heart disease during follow-ups.
Fetal of non-fetal ischemic stroke12 monthsThe incidence of fetal of non-fetal ischemic stroke during follow-ups.
Revascularization12 monthsThe incidence of revascularization during follow-ups.
Chest pain requiring readmission12 monthsThe incidence of chest pain requiring readmission during follow-ups.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026